Cannabis Law Report

DECEMBER 14, 2021

IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. Food and Drug Administration (FDA) on December 1, 2021. www.igcinc.us , www.igcpharma.com.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. 3 Nature Aging | VOL 1 | July 2021 | p.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

AUGUST 9, 2021

August 2, 2021 – August 6, 2021. Investors will continue to keep an eye on several ongoing clinical trials, as well as private companies that are gearing up to go public over the coming quarters. PsyIndex Weekly Update. Market Performance.

Clinical Trials 105

Clinical Trials Decriminalization Research and Development Treatment 105

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

JUNE 7, 2021

May 31, 2021 – June 4, 2021. Filament Health partnered with TrPR Psychedelic Research Program at UCSF to advance drug candidates through clinical trials. The PsyIndex moved marginally higher last week as new companies continue to announce plans to go public. With the recent launch of the first U.S. Powered by.

Research and Development 98

Research and Development Clinical Trials Extraction Retail 98

TheAnswerPage

AUGUST 22, 2021

Currently, clinical trials are evaluating CBD’s analgesic, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, antitumor and anti-hypoxia/ischemia properties. The range of conditions for which CBD has been (or is being) assessed is quite diverse.

Clinical Trials 59

Clinical Trials Conditions CBD 59

Cannabis Law Report

JUNE 21, 2021

June 14, 2021 – June 18, 2021. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. PsyIndex Weekly Update. The PsyIndex gave up ground last week following the prior week’s robust gains. ATAI Life Sciences N.V. Market Performance. Press Release. Entheon Biomedical Corp. Press Release.

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Cannabis Law Report

AUGUST 12, 2021

Net loss for the six months ended 30 June 2021 was $30.2 Net loss for the six months ended 30 June 2021 was $30.2 Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

TheAnswerPage

JUNE 17, 2021

Currently, clinical trials are evaluating CBD’s analgesic, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, antitumor and anti-hypoxia/ischemia properties. The range of conditions for which CBD has been (or is being) assessed is quite diverse.

Clinical Trials 52

Clinical Trials Conditions CBD 52

TheAnswerPage

JUNE 17, 2021

Currently, clinical trials are evaluating CBD’s analgesic, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, antitumor and anti-hypoxia/ischemia properties. The range of conditions for which CBD has been (or is being) assessed is quite diverse.

Clinical Trials 52

Clinical Trials Conditions CBD 52

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. The Marijuana Regulatory Agency issued a request for proposals for the 2021 Veteran Marijuana Research Grant Program on Tuesday, June 1. Read more at.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

MAY 26, 2023

Gardiner, Rocky Swanson May 24, 2023 After a period of intense market interest in 2021, investment in psychedelics has cooled somewhat, although results from clinical trials remain positive. Here’s the introduction to the piece By Kimberly Burns, Rose M. Carter, Karen M. Lexpert spoke with Kimberly Burns, Rose M.

Clinical Trials 52

Clinical Trials 52

TheAnswerPage

JUNE 19, 2021

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. 29 May 2021 [link]. Sandip Patel, Reid Grinspoon, Bradley Fleming, Lauren A. See the Answer.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

TheAnswerPage

NOVEMBER 30, 2021

Psilocybin, the hallucinogen found in “magic mushrooms” has been used in clinical trials. Schedule I substances cannot be used in clinical trials n the US (without special permission). Is psilocybin classified as a scheduled substance under the Controlled Substances Act? THC is also a schedule I substance.)

Clinical Trials 52

Clinical Trials Safety Treatment THC 52

Cannabis Law Report

OCTOBER 15, 2021

At Kidney Week 2021, Goldfinch Bio will present multiple e-posters, including: The design of TRACTION-2, the ongoing Phase 2 clinical trial evaluating GFB-887 for the treatment of focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy (DN). Presentations at ASN Kidney Week 2021, November 4-7, 2021.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

TheAnswerPage

NOVEMBER 29, 2021

What serious adverse events have been noted in psilocybin clinical trials? The serious adverse events (AE) reported in the psilocybin clinical trial conducted by Compass Pathways occurred in 12 of the 233 patients and included suicidal behavior, suicidal ideation, and intentional self-injury.

Clinical Trials 52

Clinical Trials Events Patients 52

Cannabis Law Report

FEBRUARY 10, 2022

The report includes: A deep dive into psychedelic drug policy reform efforts and successes in 2021, with a focus on key jurisdictions including the U.S. A look at key research and clinical trials that were published in 2021, with analysis of themes like microdosing and SSRI interactions. and Canada.

Clinical Trials 52

Clinical Trials Microdosing Pharmaceutical Policy 52

Cannabis Law Report

JANUARY 10, 2022

Minor Cannabinoids Market Size, Share & Trends Analysis Report by Product (CBG, CBC, CBN, THCV, CBGA), by Application (Pain Management, Neurological Disorders), and Segment Forecasts, 2021-2028” report has been added to ResearchAndMarkets.com’s offering. For instance, as of June 2021, InMed Pharmaceuticals, Inc.,

Cannabinoids 52

Cannabinoids Clinical Trials Research and Development Supply Chain 52

Cannabis Law Report

JULY 28, 2021

million fundraise and admission to the standard segment of the Official List and to trading on the London Stock Exchange Group plc’s Main Market for listed securities in May 2021 (together “Admission”). Publication of its final results for the year ended 31 May 2021 will be approximately one month later.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

TheAnswerPage

MAY 23, 2022

Currently, clinical trials are evaluating CBD’s analgesic, neuroprotective, antiepileptic, anxiolytic, antipsychotic, anti-inflammatory, antitumor and anti-hypoxia/ischemia properties. The range of conditions for which CBD has been (or is being) assessed is quite diverse.

Clinical Trials 59

Clinical Trials Conditions CBD 59

Cannabis Law Report

JUNE 24, 2022

We have covered this but it is interesting to see theat the Guardian have picked up the story… All clinical trials into the psychoactive drug MDMA are being reviewed by Canadian regulators after complaints about abuse of study participants by a trailblazing American psychedelic research organization.

Clinical Trials 52

Clinical Trials Treatment Pharmaceutical Medicine 52

Cannabis Law Report

DECEMBER 1, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. Date: December 2, 2021. Dates: December 8-9, 2021. Registration: Click here.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 15, 2021

In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.

DEA 96

DEA Clinical Trials Extraction Marijuana 96

SpeedWeed

AUGUST 16, 2021

LAS VEGAS, NV [August 16, 2021] – Cannabis Conference , produced by parent company GIE Media Inc. 24-26, 2021, at Paris Las Vegas Hotel & Casino. We couldn’t be more thrilled to host Dr. Sisley at Cannabis Conference 2021 as our Day 2 keynote,” said Cannabis Conference Programming Director Cassie Neiden Tomaselli. “Dr.

Media 52

Media Clinical Trials DEA Hemp 52

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 23, 2021

& Notice of 2021 Final Results. . At the end of the programme, Evotec will provide the Company with a submission-ready regulatory document which will be used for submissions to regulatory agencies, as well as drug-batch approved and ready for First Time in Human clinical trials. Oxford Cannabinoid Technologies Holdings plc.

Cannabinoids 98

Cannabinoids Research and Development Clinical Trials Packaging 98

Cannabis Law Report

OCTOBER 29, 2021

(NYSE American: IGC) announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company’s 2022 fiscal year. During the six months ended September 30, 2021, the Company raised approximately $4.1 million for the three months ended September 30, 2021, from approximately $1.48

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

TheAnswerPage

JULY 13, 2021

Has CBDV been evaluated as an anti-seizure medication in clinical trials? Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. That trial did not continue.

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

TheAnswerPage

JANUARY 21, 2021

Note: The results of preclinical trials are NOT equivalent to clinical trials. Over the past two decades, PRECLINICAL data indicate that THC, CBD, as well as some synthetic cannabinoids induce apoptosis of cancer cells and inhibit tumor proliferation, metastasis, and angiogenesis. See Answer. See Answer.

Clinical Trials 52

Clinical Trials Data Cannabinoids THC 52

Cannabis Law Report

AUGUST 17, 2021

Phase 3 planning for TrustTSC trial ongoing with first patient expected to be enrolled in Q4 2021. A global Phase 3 randomized, double blind, placebo-controlled trial (TrustTSC) of adjunctive ganaxolone in approximately 160 TSC patients is expected to begin enrollment during Q4 2021. RADNOR, Pa.–(BUSINESS

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 9, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

Pharmaceutical 97

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 97

TheAnswerPage

MAY 29, 2021

LO69: Haloperidol versus ondansetron for hyperemesis due to cannabis (HaVOC): A randomized, controlled clinical trial. Ruberto, A., Sivilotti, M., Forrester, S., Crawford, F., & Day, A. CJEM, 22(S1), S32-S33. doi:10.1017/cem.2020.124. See the Answer.

Clinical Trials 52

Clinical Trials Cannabinoids Treatment Recreational 52

TheAnswerPage

MAY 25, 2022

The results of recent clinical trials indicate that Cannabidiol (CBD) reduces seizures among patients with refractory epilepsies of various etiologies. Most of these clinical studies report efficacy over short time periods (. 29 May 2021 [link]. Sandip Patel, Reid Grinspoon, Bradley Fleming, Lauren A. See the Answer.

Clinical Trials 52

Clinical Trials Epilepsy Treatment CBD 52

Cannabis Law Report

SEPTEMBER 6, 2021

DUBLIN–(BUSINESS WIRE)–The “Medical Cannabis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. during 2021-2026. The global medical cannabis market exhibited strong growth during 2015-2020.

Chronic Pain 86

Chronic Pain Research and Development Clinical Trials Epilepsy 86

Cannabis Law Report

AUGUST 10, 2021

CSE: LOAN ) (FSE: O3X) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) is pleased to announce the signing of a definitive agreement on August 6th 2021 memorializing the Global Wellness Strategies , Inc. binding letter of intent signed on July 12th 2021 to purchase certain assets of Cannvalate Pty Ltd. (“CV”)

Chronic Pain 105

Chronic Pain Clinical Trials Research and Development Events 105

The Cannigma

APRIL 12, 2023

In 2021, MoreBetter used its web-based software to track over 350 people using a CBN tincture from CBDistillery. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. It also, allegedly, helps with sleep (more on that below).

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

JUNE 23, 2021

NEO: AWKN) began trading today, June 23, 2021, on the NEO Exchange Inc. The company has plans to open three UK psychedelic-assisted psychotherapy clinics where it will deliver ketamine-assisted therapies near term and MDMA when they secure authorization in 2021 (Bristol, London, and Manchester). David Nutt), starts in Q4 2021.

Clinical Trials 110

Clinical Trials Therapy Research and Development Treatment 110